Management of dupilumab-associated conjunctivitis in atopic dermatitis

Aszodi, Nora; Thurau, Stephan; Seegraeber, Marlene; de Bruin-Weller, Marjolein und Wollenberg, Andreas (2019): Management of dupilumab-associated conjunctivitis in atopic dermatitis. In: Journal der Deutschen Dermatologischen Gesellschaft, Vol. 17, No. 5: pp. 488-492

Abstract

Since September 2017, the monoclonal antibody dupilumab (Dupixent (R)) has been approved in the EU for the treatment of moderate-to-severe atopic dermatitis. By blocking IL-4 and IL-13 signaling pathways, dupilumab improves both objective signs and subjective symptoms of the disease. Blocking of the IL-4aR a subunit leads to improvement of the skin's barrier function and reduction in Th2-mediated inflammation. While the rate of adverse events on dupilumab is generally low, mild-to-moderate conjunctivitis associated with redness as well as a burning and foreign body sensation has been reported in up to 28 % of patients. Treatment options include topical corticosteroids and topical calcineurin inhibitors. The present review highlights the clinical presentation of dupilumab-associated conjunctivitis and addresses pharmacological and non-pharmacological options available for the treatment of this clinically highly relevant condition.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 1610-0379
• Language: English